ABCL:NASDAQ
AbCellera Biologics Inc
$10.46
arrow_downward
-5.34%(-0.59) 1D
$10.35
arrow_downward
-1.05% (-0.11)bedtimeAfter hours
Closed: Sep 10, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$10.79
High
$11.07
Low
$10.42
Mkt. cap
3.39B
Avg. vol.
8.26M
Volume
0.00
52-wk high
$12.58
52-wk low
$2.74
EPS
-$0.54
Beta
1.32
Shares outstanding
324.05M
No. of employees
562
Open
$10.79
High
$11.07
Low
$10.42
Mkt. cap
3.39B
Avg. vol.
8.26M
Volume
0.00
52-wk high
$12.58
52-wk low
$2.74
EPS
-$0.54
Beta
1.32
Shares outstanding
324.05M
No. of employees
562
News stories
From web sources and news partners
marketscreener.com
·
20 hours ago
ABCL's Growth Story Comes From Every Corner
Investing.com
·
1 day ago
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com